These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16065056)

  • 1. Confusion over Article 8.
    Tambuyzer E
    EMBO Rep; 2005 Aug; 6(8):690. PubMed ID: 16065056
    [No Abstract]   [Full Text] [Related]  

  • 2. Adopting an orphan.
    Rinaldi A
    EMBO Rep; 2005 Jun; 6(6):507-10. PubMed ID: 15940282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 4. Policy alternatives for treatments for rare diseases.
    Panju AH; Bell CM
    CMAJ; 2010 Nov; 182(17):E787-92. PubMed ID: 20624867
    [No Abstract]   [Full Text] [Related]  

  • 5. Time to revisit the orphan drug law.
    Garattini S
    Eur J Clin Pharmacol; 2012 Feb; 68(2):113. PubMed ID: 21842335
    [No Abstract]   [Full Text] [Related]  

  • 6. Rare disease resources not as rare as one might think.
    Burnworth MT
    Am J Health Syst Pharm; 2013 Jun; 70(12):1013-4. PubMed ID: 23719873
    [No Abstract]   [Full Text] [Related]  

  • 7. Why we should care about ultra-rare disease.
    Harari S
    Eur Respir Rev; 2016 Jun; 25(140):101-3. PubMed ID: 27246584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orphan drugs revisited.
    McCabe C; Tsuchiya A; Claxton K; Raftery J
    QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
    [No Abstract]   [Full Text] [Related]  

  • 10. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
    Brabers AE; Moors EH; van Weely S; de Vrueh RL
    Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should off-label drug use be off-the-table?
    Rivkees SA
    J Pediatr Endocrinol Metab; 2007 Feb; 20(2):171-2. PubMed ID: 17396432
    [No Abstract]   [Full Text] [Related]  

  • 13. Does orphan drug legislation really answer the needs of patients?
    Haffner ME; Torrent-Farnell J; Maher PD
    Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
    [No Abstract]   [Full Text] [Related]  

  • 14. The challenges of pharmacoepidemiology of orphan drugs in rare diseases.
    Lapeyre-Mestre M
    Therapie; 2020 Apr; 75(2):215-220. PubMed ID: 32164974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outrageous prices of orphan drugs: a call for collaboration.
    Luzzatto L; Hyry HI; Schieppati A; Costa E; Simoens S; Schaefer F; Roos JCP; Merlini G; Kääriäinen H; Garattini S; Hollak CE; Remuzzi G;
    Lancet; 2018 Sep; 392(10149):791-794. PubMed ID: 30037734
    [No Abstract]   [Full Text] [Related]  

  • 16. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 17. The orphan drug backlash.
    Maeder T
    Sci Am; 2003 May; 288(5):80-7. PubMed ID: 12701333
    [No Abstract]   [Full Text] [Related]  

  • 18. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
    Schlander M; Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
    Tambuyzer E
    Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Orphan Drug Act Revisited.
    Thomas S; Caplan A
    JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.